Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614015 | 0.94 | PTGS2 (0.44) | QDPRGAAMEN1LMNAMAPT | |
| SCHEMBL2070644 | 0.84 | ESR2 (0.39) | MEN1MAPTALOX15ALOX12MAPK1 | |
| SCHEMBL616469 | 0.81 | ESR1 (0.43) | QDPRALOX5RARARARBRARG | |
| SCHEMBL612956 | 0.81 | MAOB (0.49) | QDPRGAAMEN1LMNAMAPT | |
| SCHEMBL615914 | 0.79 | HSD17B1 (0.41) | PTGS2RARARARGNR1H4ESR1 | |
| SCHEMBL616661 | 0.78 | ESR1 (0.43) | ALOX5RARARARBRARGNR1H4 | |
| SCHEMBL4295886 | 0.77 | RARA (0.42) | MEN1MAPK1KMT2AHSD17B10PTGS2 | |
| SCHEMBL2069685 | 0.77 | RARA (0.42) | MEN1KMT2APTGS2PTGS1RARA | |
| SCHEMBL12022858 | 0.76 | MAPT (0.38) | QDPRMAPTNPSR1PTGS2ALOX5 | |
| SCHEMBL616913 | 0.72 | ALOX15 (0.46) | GAAMEN1MAPTALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | claimed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | claimed |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | MARSHALL EDWARDS, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2334296-A1 | IMMUNOMODULATING ACTIVITIES | Novogen Research Pty. Ltd. (AU) | 2011-06-22 | — | — | EP | disclosed |
| US-7906660-B2 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| WO-2010022467-A1 | IMMUNOMODULATING ACTIVITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2010-03-04 | — | — | WO | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | disclosed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | disclosed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | QDPR 359/4885GAA 2354/4885MEN1 1170/4885 |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | CD4, NFATC1, HRH2 | QDPR 3482/4885GAA 2658/4885MEN1 4633/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | QDPR 1098/4885GAA 517/4885MEN1 1052/4885 |
| US-20050143588-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | QDPR 359/4885GAA 2354/4885MEN1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.